Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranolazine for Prevention of Perioperative Myocardial Injury
NCT01810796Phase 3Unknown
- Sponsor
- Hadassah Medical Organization
- Start
- Dec 2013
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ranolazine in Myocardial injury, sponsored by Hadassah Medical Organization. Primary endpoint: Postoperative troponin at 3 days. Status: unknown.
02
Drugs
ranolazine
03
Conditions
Myocardial injury
Beyond the preview
Go deeper on NCT01810796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01810796.